OneMedNet Secures Neuro Data Deal, Bolsters AI-Driven RWD Offering

Event summary

  • OneMedNet has entered a multi-year data licensing agreement with Risorius, a neurotechnology company.
  • The agreement involves Risorius licensing access to OneMedNet’s EEG and PSG waveform data, paired with clinical context.
  • The deal is expected to generate millions of dollars in incremental recurring revenue for OneMedNet.
  • Risorius selected OneMedNet based on data quality, volume, and a practical licensing approach.
  • The agreement was executed rapidly, highlighting commercial alignment and perceived value.

The big picture

The partnership reflects a broader trend of AI-native companies leveraging real-world data to develop digital biomarkers and accelerate CNS drug development. OneMedNet’s ability to secure this deal positions it as a key infrastructure provider within a rapidly growing market, but also highlights the increasing importance of regulatory-grade data in the AI-driven healthcare landscape. The deal's rapid closure suggests OneMedNet’s data assets and delivery model are increasingly attractive to specialized research firms.

What we're watching

Execution Risk
The rapid execution of this deal suggests strong alignment, but OneMedNet must ensure it can consistently deliver the promised data volume and quality to maintain Risorius’s satisfaction and avoid churn.
Competitive Landscape
The deal underscores the growing demand for neuro-focused RWD, and OneMedNet will face increasing competition from other data providers seeking to capitalize on this trend.
Expansion Potential
Risorius’s stated intention to expand its database and R&D projects suggests potential for further data licensing agreements with OneMedNet, but hinges on the initial project’s success.

Related topics

Technology